SOPHiA Genetics SA (NASDAQ:SOPH) Short Interest Update

SOPHiA Genetics SA (NASDAQ:SOPH) saw a large increase in short interest in August. As of August 31st, there was short interest totalling 445,400 shares, an increase of 85.1% from the August 15th total of 240,600 shares. Based on an average trading volume of 235,200 shares, the short-interest ratio is presently 1.9 days. Currently, 0.9% of the company’s stock are sold short.

Several brokerages have weighed in on SOPH. Cowen began coverage on shares of SOPHiA Genetics in a report on Tuesday, August 17th. They set an “outperform” rating for the company. Credit Suisse Group assumed coverage on shares of SOPHiA Genetics in a report on Tuesday, August 17th. They set an “outperform” rating and a $22.00 price objective for the company. Morgan Stanley assumed coverage on shares of SOPHiA Genetics in a research report on Tuesday, August 17th. They issued an “overweight” rating and a $24.00 price target on the stock. Finally, JPMorgan Chase & Co. assumed coverage on shares of SOPHiA Genetics in a research report on Tuesday, August 17th. They issued an “overweight” rating and a $23.00 price target on the stock.

Shares of SOPHiA Genetics stock traded up $0.15 during trading hours on Friday, reaching $17.43. The company’s stock had a trading volume of 26 shares, compared to its average volume of 153,646. SOPHiA Genetics has a one year low of $14.88 and a one year high of $19.80.

SOPHiA Genetics (NASDAQ:SOPH) last posted its quarterly earnings results on Wednesday, September 8th. The company reported ($0.31) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.39) by $0.08. On average, research analysts expect that SOPHiA Genetics will post -1.49 earnings per share for the current year.

About SOPHiA Genetics

SOPHiA GENETICS SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM(TM) Platform, a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities.

Recommended Story: Momentum Indicators

Receive News & Ratings for SOPHiA Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SOPHiA Genetics and related companies with MarketBeat.com's FREE daily email newsletter.